ICU Medical (NASDAQ:ICUI) Releases FY 2026 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 8.600-9.000 for the period, compared to the consensus EPS estimate of 7.830. The company issued revenue guidance of -.

Analyst Ratings Changes

Several research firms have recently commented on ICUI. Needham & Company LLC raised their target price on shares of ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research note on Friday. Sanford C. Bernstein lowered shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Zacks Research cut shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Piper Sandler raised their price objective on shares of ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $192.80.

ICU Medical Stock Up 10.9%

Shares of NASDAQ:ICUI opened at $184.56 on Friday. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $4.61 billion, a P/E ratio of 156.41, a P/E/G ratio of 2.32 and a beta of 0.74. ICU Medical has a 52-week low of $107.00 and a 52-week high of $192.85. The stock’s fifty day simple moving average is $151.64 and its 200-day simple moving average is $141.02.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. The business had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.94%. The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, equities research analysts forecast that ICU Medical will post 6.51 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the transaction, the vice president directly owned 19,460 shares in the company, valued at approximately $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director owned 7,960 shares of the company’s stock, valued at $978,363.60. This trade represents a 23.34% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company’s stock.

Key Headlines Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

Institutional Trading of ICU Medical

Several institutional investors have recently made changes to their positions in the stock. Millennium Management LLC increased its position in ICU Medical by 173.4% during the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after purchasing an additional 690,694 shares in the last quarter. UBS Group AG grew its stake in ICU Medical by 239.8% during the third quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock worth $46,371,000 after buying an additional 272,782 shares during the period. Ameriprise Financial Inc. increased its position in shares of ICU Medical by 34.0% in the third quarter. Ameriprise Financial Inc. now owns 803,542 shares of the medical instruments supplier’s stock worth $96,393,000 after acquiring an additional 203,746 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of ICU Medical by 16.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 872,993 shares of the medical instruments supplier’s stock valued at $104,718,000 after acquiring an additional 126,072 shares during the period. Finally, Janus Henderson Group PLC raised its stake in shares of ICU Medical by 4.2% in the 4th quarter. Janus Henderson Group PLC now owns 2,576,756 shares of the medical instruments supplier’s stock valued at $367,625,000 after acquiring an additional 103,220 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.